Moderna and Merck Report Results from the P-IIb (KEYNOTE-942) Study of mRNA-4157 (V940) + Keytruda (pembrolizumab) for Resected High-Risk Melanoma
Shots:
- The P-IIb (KEYNOTE-942) study investigates mRNA-4157 (1mg, Q3W for nine doses) and Keytruda [200mg, Q3W up to 18 cycles (~1yr.)] vs Keytruda monotx. in patients (n=157) with high-risk stage III/IV melanoma
- In a median follow-up of ~3yrs., the combination of mRNA-4157 (V940) & Keytruda demonstrated significant improvements incl. 49% of RFS and a 62% of DMFS vs Keytruda monotx.
- On the basis of these results, the US FDA and the EMA granted BTD and PRIME designation respectively, to mRNA-4157 (V940) + Keytruda for adjuvant treatment of patients with high-risk melanoma
Ref: Moderna | Image: Moderna
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
